Back to News
Market Impact: 0.22
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
Source: Business Wire
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Bristol Myers Squibb presented two-year Sotyktu data in adults with psoriatic arthritis showing durable efficacy and a consistent safety profile. The update supports the long-term clinical positioning of Sotyktu, though the headline provides no detailed efficacy metrics, safety-event rates, or commercial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
BMY0.68
More News
- Pokémon card curbs send shares of Japanese online marketplace Mercari on a bumpy ride
- US to Sell F-35s to Saudi Arabia in $24.3 Billion Deal
- After being sidelined, Boeing's Starliner to get starring role in NASA's spaceflight plans
- Jensen Huang says Nvidia will sell twice as many chips next year
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- Generac shares surge on big Amazon deal. Wall Street thinks the generator stock has more to go